RxDoctor Payments Data

Marc Fisk, DO

Cardiovascular Disease · West Orange, NJNPI 1669472213

Payments from drug & device makers

$1,751in general payments, 2019–2025

Across 113 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$679
  • Abbott$257
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$161
  • Novo Nordisk$87
  • Heartflow, Inc.$84
  • Johnson & Johnson$73
  • plus $410 from 15 others

What the payments were for

  • Food & beverage$1,73999%
  • Other$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,751 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$213,740
Medicare patients
868
Services billed
2,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$227,179
BrilintaTicagrelor118$90,252
XareltoRivaroxaban47$53,242
EntrestoSacubitril/Valsartan47$43,580
JardianceEmpagliflozin42$39,534
MultaqDronedarone Hcl24$27,163
Ranolazine ErRanolazine147$12,974
VascepaIcosapent Ethyl27$9,135
Atorvastatin Calcium538$5,262
Rosuvastatin Calcium226$4,256
Metoprolol Succinate307$4,115
Ezetimibe116$3,099
Hydralazine Hcl152$2,708
ClopidogrelClopidogrel Bisulfate166$2,009
Isosorbide Dinitrate25$1,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$227,179235 claims
AstraZenecaBrilinta$28$90,252118 claims
Johnson & JohnsonXarelto$73$53,24247 claims
NovartisEntresto$679$43,58047 claims
Sanofi-aventis U.S. LLCMultaq$60$27,16324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →